Coccidioidomycosis in Patients Treated With Ruxolitinib.

Clicks: 239
ID: 108013
2020
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #28 of 229 articles by views in Open forum infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 229 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
We report 8 cases of coccidioidomycosis associated with ruxolitinib treatment. Among 135 patients living in the coccidioidal-endemic region receiving ruxolitinib, 5 cases were diagnosed after starting and 4 had extrathoracic dissemination. Periodic serological screening while on ruxolitinib is warranted for patients residing in the coccidioidal-endemic region.
Reference Key
kusne2020coccidioidomycosisopen Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Kusne, Yael;Kimes, Kathryn E;Feller, Fionna F;Patron, Roberto;Banacloche, Juan Gea;Blair, Janis E;Vikram, Holenarasipur R;Ampel, Neil M;
Journal Open forum infectious diseases
Year 2020
DOI
10.1093/ofid/ofaa167
URL
Keywords
fungal infections ruxolitinib coccidioidomycosis immunocompromised host

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.